Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.
Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
GSK gets the vaccine edge on Pfizer
US experts favour GSK’s RSV vaccine over Pfizer’s, but both could be on the market soon.
Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.